Commentary: Is angiotensin II a game changer for vasoplegia after cardiac surgery, or is the jury still out?

J Thorac Cardiovasc Surg. 2022 Apr;163(4):1415-1416. doi: 10.1016/j.jtcvs.2021.03.074. Epub 2021 Mar 26.

Author

Subhasis Chatterjee¹

Affiliation

¹ Divisions of General Surgery and Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine and Department of Cardiovascular Surgery, Texas Heart Institute, Houston, Tex. Electronic address: subhasis.chatterjee@bcm.edu.

PMID: 33888313
DOI: 10.1016/j.jtcvs.2021.03.074

No abstract available

Publication types

Editorial
Comment

MeSH terms

Angiotensin II
Cardiac Surgical Procedures* / adverse effects
Cardiopulmonary Bypass / adverse effects
Humans
Vasoplegia* / drug therapy
Vasoplegia* / etiology

Substances

Angiotensin II